Merck KGaA, Darmstadt, Germany, Donates two Million N95 Medical Grade Masks
- Protective masks go to Germany, France and the United States, among others
- Merck KGaA, Darmstadt, Germany, is supporting fight against the Covid-19 pandemic through multifaceted activities
Merck KGaA, Darmstadt, Germany, a leading science and technology company, is donating a total of two million N95 medical grade masks in Germany, France, and the United States, among others. The company is covering the costs of purchasing and transporting the protective equipment. The donation is mainly intended to support healthcare workers; the relevant authorities and organizations will handle the distribution of the masks.
“During these unprecedented times, we are grateful for the dedication and great work of all those on the Covid-19 front lines,” said Belén Garijo, Member of the Executive Board and CEO Healthcare of Merck KGaA, Darmstadt, Germany. “To help protect more than 30,000 healthcare professionals, we are donating up to a month’s supply of the much needed N95 masks. At Merck, KGaA, Darmstadt, Germany, we are focused on advancing human progress and continue to provide our resources and full dedication to overcome the Covid-19 pandemic.”
Moreover, Merck KGaA, Darmstadt, Germany, is supporting the global fight against Covid-19 through a wide range of actions. For example, the company is cooperating with other pharmaceutical and life science companies as well as the Bill & Melinda Gates Foundation to develop, manufacture and provide vaccines, diagnostics and treatment options for Covid-19. The company’s Life Science business is supporting the Jenner Institute in reaching an initial milestone for the industrial production of a potential Covid-19 vaccine. In addition, Merck KGaA, Darmstadt, Germany and its affiliates have set up their own production capacities for disinfectant at sites in Darmstadt and Wiesbaden, Germany, as well as Rio de Janeiro, Brazil and Norwood, US, amongst others.
In 2019, the company awarded the Future Insight Prize, a research grant worth up to € 1 million, for superb scientific achievements in the field of pandemic preparedness to Pardis Sabeti from Harvard University and the Broad Institute as well as to James Crowe from Vanderbilt University Medical Center. Like many scientists worldwide, they are currently working hard to identify diagnostics and therapeutic options for Covid-19 infections.
More information about the work Merck KGaA, Darmstadt, Germany, is doing to help fight Covid-19 can be found on the company website at https://www.emdgroup.com/de/company/press/press-kits/corona-pandemic.html
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Merck KGaA, Darmstadt, Germany today announced that updated data from the ongoing, single-arm Phase II VISION study evaluating tepotinib* were published.